FINWIRES · TerminalLIVE
FINWIRES

HKG:6887

8 stories mentioning HKG:6887Updated 4d ago

Every FINWIRES story that references HKG:6887, newest first.

Asia

Sunshine Lake Pharma Wins China Marketing Approval for Insulin Degludec

Sunshine Lake Pharma (HKG:6887) posted that China's National Medical Products Administration approved the marketing of its Insulin Degludec Injection, according to a Thursday Hong Kong bourse filing.The long-acting basal insulin, developed in-house, received approval in both cartridge and prefilled pen formats.The company said the once-daily treatment provides blood glucose control for more than 42 hours and offers greater dosing flexibility.

HKG:6887
Asia

Sunshine Lake Pharma Controlling Shareholder to Boost Ownership

Sunshine Lake Pharma's (HKG:6887) controlling shareholder plans to increase his stake by purchasing between HK$300 million and HK$600 million of the company's shares in the open market over the next six months, according to a Monday Hong Kong bourse filing.The company said Zhang Yushuai currently controls about 294 million shares, representing 51.11% of its issued shares, excluding treasury shares.

HKG:6887
Asia

Sunshine Lake Pharma to Establish Investment Vehicle With Controlling Shareholder

Sunshine Lake Pharma (HKG:6887) is establishing a partnership fund to invest in companies operating in the healthcare, biomedicine, and artificial intelligence space, according to a Hong Kong bourse filing Friday.The firm will establish Shenzhen Dongyangguang Houde Jianxing Venture Investment Fund Partnership with Shenzhen HEC Technology and Zhejiang HEC Health, its controlling shareholder, to invest in leading start-up projects as part of a broader strategy to expand its drug pipeline.Sunshine Lake will contribute 500 million yuan to the fund for a 25% stake, with a further 1.5 billion yuan coming from Zhejiang HEC Health for 74.9% ownership.Shenzhen HEC Technology will invest a nominal 2 million yuan for 0.1% of the fund and serve as the general partner of the investment vehicle.

HKG:6887
Asia

Sunshine Lake Pharma Appoints Chairman

Sunshine Lake Pharma (HKG:6887) said Zhang Yingjun was elected as chairman of the company's board, according to a Thursday filing with the Hong Kong bourse.The appointment will be effective until the company's next annual meeting.

HKG:6887
Asia

China Accepts Sunshine Lake Pharma's Clinical Trial Application for Colorectal Cancer Drug

Sunshine Lake Pharma (HKG:6887) said China's drug regulator accepted a clinical trial application for HEC-921, its experimental LY6G6D/4-1BB bispecific antibody for advanced solid tumors, according to a Thursday Hong Kong bourse filing.The company said the phase 1 study is expected to begin in 2026.HEC-921 is primarily being developed for LY6G6D-positive colorectal cancer, the filing said.

HKG:6887
Asia

Sunshine Lake Pharma Completes Hong Kong-Listed Share Full Circulation

Sunshine Lake Pharma (HKG:6887) completed the conversion of nearly 208.4 million domestic shares into Hong Kong-listed shares on Thursday, according to a same-day filing with the Hong Kong bourse.The listing of the converted shares on the Hong Kong bourse is expected to begin at 9:00 am on Friday.

HKG:6887
Asia

Sunshine Lake Pharma Wins HKEX Nod for Hong Kong Share Full Circulation

Sunshine Lake Pharma (HKG:6887) said the Hong Kong Stock Exchange has granted listing approval for its Hong Kong share full circulation application, according to a Wednesday bourse filing.Shares of the pharmaceutical firm were up nearly 1% in Thursday morning trade.The approval covers the conversion of about 208.4 million domestic shares into Hong Kong-listed shares.The converted shares represent about 36.1% of the company's total issued share capital.Upon completion, Hong Kong-listed shares will account for about 55.7% of the company's total share capital, up from 19.6% before the conversion.

HKG:6887
Asia

Sunshine Lake's Diabetes Biosimilar Approved in U.S.

Sunshine Lake Pharma's (HKG:6887) insulin glargine injection was approved by the U.S. Food and Drug Administration, the firm said Monday.The medicine, a biosimilar version of Sanofi's Lantus, is intended to treat children with type 1 diabetes and adults with type 2 diabetes.The injection will be available under the Langlara trade name.

HKG:6887

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:6887 in your portfolio
WheelAI
WheelAI
Analyze HKG:6887 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:6887